# Dexamethasone, Flurbiprofen Axetil and Long-term Survival After Lung Cancer Surgery

> **NCT03172988** · PHASE4 · TERMINATED · sponsor: **Peking University First Hospital** · enrollment: 126 (actual)

## Conditions studied

- Carcinoma, Non-Small-Cell Lung
- Surgery
- Dexamethasone
- Flubiprofen Axetil
- Long-term Effects Secondary to Cancer Therapy in Adults

## Interventions

- **DRUG:** Dexamethasone
- **DRUG:** Normal saline
- **DRUG:** Flurbiprofen axetil
- **DRUG:** Lipid microsphere

## Key facts

- **NCT ID:** NCT03172988
- **Lead sponsor:** Peking University First Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2017-08-02
- **Primary completion:** 2018-12-26
- **Final completion:** 2018-12-26
- **Target enrollment:** 126 (ACTUAL)
- **Why stopped:** Protocol violation occurred frequently during the postoperative period.
- **Last updated:** 2019-03-05

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03172988

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03172988, "Dexamethasone, Flurbiprofen Axetil and Long-term Survival After Lung Cancer Surgery". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT03172988. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*